DOHA: The latest treatment options for uterine fibroids were discussed at the latest Grand Rounds of Weill Cornell Medicine – Qatar (WCM-Q) by one of most senior obstetrician-gynaecologists.
Dr David Barlow, Director, Women’s Services, Hamad Medical Corporation (HMC), and Chair, Department of Obstetrics and Gynaecology, Women’s Hospital, discussed the most commonly used surgical procedures for removal of uterine fibroids and new drug therapies developed to manage the condition without the need for surgery.
Uterine fibroids are common non-cancerous tumours that form on the wall of the uterus.
It is believed 70 to 80 percent of women will have uterine fibroids at some point in their lives though most will not notice them because they often cause no symptoms.
“For those women who experience symptoms, these can include heavy or painful periods and pain in the abdomen or lower back.
In rare cases, uterine fibroids can affect pregnancy or cause infertility.
“Finding effective treatments for uterine fibroids is important because they affect a large number of women and can be extremely painful and distressing and can negatively affect fertility, which is very distressing. Surgical procedures and new drug therapies have proven to be effective and there have been promising new developments recently,” Dr Barlow told physicians, researchers, students and healthcare professionals attending the event.
The Grand Rounds, developed by WCM-Q’s Division of Continuing Professional Development, provides a platform for speakers to engage with healthcare professionals to disseminate knowledge of latest developments in medical technology, research and best practice. The Peninsula
